Olmesartan medoxomil/amlodipine versus olmesartan medoxomil/hydrochlorothiazide in hypertensive patients with metabolic syndrom: the OLAS study.

Trial Profile

Olmesartan medoxomil/amlodipine versus olmesartan medoxomil/hydrochlorothiazide in hypertensive patients with metabolic syndrom: the OLAS study.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2012

At a glance

  • Drugs Olmesartan medoxomil/amlodipine (Primary) ; Olmesartan medoxomil/hydrochlorothiazide (Primary) ; Olmesartan medoxomil
  • Indications Hypertension; Metabolic syndrome
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Acronyms OLAS
  • Most Recent Events

    • 13 May 2012 Status changed from not stated to completed.
    • 29 Apr 2012 Results presented at the 22nd European Meeting on Hypertension.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top